Precision Medicine in Oncology®

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the anti-cancer stem cell antibody OMP-59R5 as a treatment option for patients with metastatic pancreatic cancer.

Using blood samples collected from the Andean villagers, the laboratory at the UC Davis Genome Center uses a variety of high-throughput genetic analysis techniques to screen for genetic differences.

As PARP inhibitors continue to emerge as a novel class of anticancer agents, BMN 673 has entered late-stage clinical development as a treatment for patients with locally advanced or metastatic breast cancer whose tumors test positive for germline BRCA1/2 mutations.

An interview with Barry D. Nelkin, PhD, from Johns Hopkins, on his research investigating a promising new target in a KRAS-related pathway, cyclin-dependent kinase 5.

The members of the RAS oncogene family are central cogs in many different cell-signaling pathways, coordinate a variety of important cellular processes, and are highly mutated in a number of different cancers, including several with extremely poor prognosis.